Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

J. Motzer, Robert; Yа. Alekseev, B.; Young Rha, Sun; Porta, Camillo; Eto, Masatoshi; Powles, Thomas; Grünwald, Viktor; E. Hutson, Thomas; Kopyltsov, Evgeny; José Méndez-Vidal, María; Kozlov, Vadim; Alyasova, Anna; Hong, Sung‐Hoo; Kapoor, Anil; Alonso Gordoa, Teresa; R. Merchan, Jaime; Winquist, Eric; Maroto, Pablo; C. Goh, Jeffrey; Kim, Miso; Gurney, Howard; Patel, Vijay; Peer, Avivit; Procopio, Giuseppe; Takagi, Toshio; Melichar, Bohuslav; Rolland, Frédéric; De Giorgi, Ugo; Wong, Shirley; Bedke, Jens; Schmidinger, Manuela; E. Dutcus, Corina; D. Smith, Alan; Dutta, Lea; Mody, Kalgi; F. Perini, Rodolfo; Xing, Dongyuan; K. Choueiri, Toni

doi:10.1056/nejmoa2035716

Public

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

Published in New England Journal of Medicine • Feb 13, 2021

Authors:

Robert J. Motzer

B. Yа. Alekseev

Sun Young Rha

Abstract

BACKGROUND: Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear. METHODS: In this phase 3 trial, we randomly assigned (in a 1:1:1 ratio) patients with advanced rena...

Subject

Lenvatinib

Pembrolizumab

Everolimus

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!